Enanta Pharmaceuticals, Inc. (ENTA) Financials

ENTA Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 428.5 million 236.6 million
2023-09-30 462.3 million 245.5 million
2023-06-30 495.2 million 257.4 million
2023-03-31 326.4 million 57.1 million

ENTA Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -25.8 million 8.1 million
2023-09-30 -23.0 million 6.7 million
2023-06-30 -34.3 million 7.0 million
2023-03-31 -16.2 million 7.4 million

ENTA Net Income

No data available :(

ENTA Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 337.2 million - 25.5 million
2023-09-30 369.9 million - 26.5 million
2023-06-30 386.6 million - 27.7 million
2023-03-31 210.1 million - 28.0 million

ENTA Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 21.1 million
2023-09-30 21.0 million
2023-06-30 21.1 million
2023-03-31 21.0 million

ENTA Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 787000 36.4 million 16.5 million -
2023-09-30 1.4 million 36.2 million 13.8 million -
2023-06-30 2.2 million 43.0 million 12.6 million -
2023-03-31 2.4 million 43.5 million 13.8 million -

ENTA Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 18.0 million 642000
2023-09-30 18.9 million 669000
2023-06-30 18.9 million 651000
2023-03-31 17.8 million 540000

ENTA

Price: $13.04

52 week price:
8.08
38.97

Earnings Per Share: -6.57 USD

P/E Ratio: -1.92

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 3045

Ebitda: 15.9 million

Market Capitalization: 355.8 million

Links: